{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:46:48Z","timestamp":1791557208204,"version":"4.3.4"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82101276"],"award-info":[{"award-number":["82101276"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ondansetron is a widely used anti-emetic for the prevention and treatment of nausea and vomiting for patients in critical care. Recent retrospective cohort studies suggest the potential beneficial effects of ondansetron in critically ill patients. In this study, we investigate the impact of ondansetron use on patient outcomes after cardiac surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and Methods<\/jats:title><jats:p>The MIMIC-III database was used to identify two types of cardiac surgical patients: those who were administered early ondansetron and those who were not given this early medication in the first 48\u2005h in the postoperative period. Multivariable logistic regression was used to investigate the effect of ondansetron exposure on 90-day mortality, acute kidney injury, and malignant ventricular arrhythmias. Sensitivity analyses utilizing the inverse probability of treatment weighting and <jats:ext-link>covariate balancing propensity score models<\/jats:ext-link> were conducted to test the robustness of our findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 12.4% of patients received ondansetron. Ondansetron use was associated with a lower risk of 90-day mortality in the multivariable logistic regression model (OR: 0.31, 95% CI: 0.13 to 0.72; <jats:italic>P<\/jats:italic>\u2009=\u20090.006) and sensitivity analyses. Additionally, ondansetron exposure was associated with less postoperative acute kidney injury (OR: 0.82, 95%CI: 0.69 to 0.96; <jats:italic>P<\/jats:italic>\u2009=\u20090.017) but did not increase the risk of postoperative malignant ventricular arrhythmias (OR: 0.38, 95%CI: 0.09 to 1.16; <jats:italic>P<\/jats:italic>\u2009=\u20090.191).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In a population of cardiac surgical patients, early postoperative use of ondansetron appears to be associated with decreased 90-day mortality and acute kidney injury.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2022.885137","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T06:21:32Z","timestamp":1655360492000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Early Postoperative Ondansetron Exposure is Associated with Reduced 90-Day Mortality in Patients Undergoing Cardiac Surgery"],"prefix":"10.3389","volume":"9","author":[{"given":"Dexin","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1213\/ane.0000000000004730","article-title":"A single prophylactic dose of ondansetron given at cessation of postoperative propofol sedation decreases postoperative nausea and vomiting in cardiac surgery patients: a randomized controlled trial","volume":"131","author":"Wang","year":"2020","journal-title":"Anesth Analg"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/aca.ACA_122_17","article-title":"Prophylaxis of postoperative nausea and vomiting after cardiac surgery in high-risk patients: a randomized controlled study","volume":"21","author":"Champion","year":"2018","journal-title":"Ann Card Anaesth"},{"key":"B3","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/j.1399-6576.2010.02275.x","article-title":"Prophylactic control of post-operative nausea and vomiting using ondansetron and ramosetron after cardiac surgery","volume":"54","author":"Choi","year":"2010","journal-title":"Acta Anaesthesiol Scand"},{"key":"B4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1213\/ane.0000000000004833","article-title":"Fourth consensus guidelines for the management of postoperative nausea and vomiting","volume":"131","author":"Gan","year":"2020","journal-title":"Anesth Analg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1097\/pcc.0000000000000776","article-title":"Effect of ondansetron on QT interval in patients cared for in the PICU","volume":"17","author":"Trivedi","year":"2016","journal-title":"Pediatr Crit Care Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jpeds.2016.08.058","article-title":"Risk of ventricular arrhythmias and association with ondansetron","volume":"179","author":"Moeller","year":"2016","journal-title":"J Pediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.annemergmed.2013.10.026","article-title":"Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis","volume":"64","author":"Freedman","year":"2014","journal-title":"Ann Emerg Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1517\/14740338.2013.780026","article-title":"Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia","volume":"12","author":"Doggrell","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.phrs.2018.06.015","article-title":"Beyond a neurotransmitter: the role of serotonin in inflammation and immunity","volume":"140","author":"Wu","year":"2019","journal-title":"Pharmacol Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s10753-017-0584-7","article-title":"The 5-HT(3) receptor antagonist ondansetron attenuates pancreatic injury in cerulein-induced acute pancreatitis model","volume":"40","author":"Tsukamoto","year":"2017","journal-title":"Inflammation"},{"key":"B11","first-page":"30","article-title":"Anti-inflammatory effect of ondansetron through 5-HT3 receptors on TNBS-induced colitis in rat","volume":"11","author":"Motavallian-Naeini","year":"2012","journal-title":"Excli J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.resuscitation.2010.11.007","article-title":"Ondansetron attenuates hepatic injury via p38 MAPK-dependent pathway in a rat haemorrhagic shock model","volume":"82","author":"Liu","year":"2011","journal-title":"Resuscitation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ejphar.2014.05.050","article-title":"Tropisetron attenuates cisplatin-induced nephrotoxicity in mice","volume":"738","author":"Zirak","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/1440-1681.12373","article-title":"Tropisetron ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats","volume":"42","author":"Barzegar-Fallah","year":"2015","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejphar.2015.10.019","article-title":"Inhibition of calcineurin\/NFAT pathway plays an essential role in renoprotective effect of tropisetron in early stage of diabetic nephropathy","volume":"767","author":"Barzegar-Fallah","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"ofab336","DOI":"10.1093\/ofid\/ofab336","article-title":"Reduced mortality with ondansetron use in SARS-CoV-2-infected inpatients","volume":"8","author":"Bayat","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8850666211073582","DOI":"10.1177\/08850666211073582","article-title":"Kidney and mortality outcomes associated with ondansetron in critically ill patients","author":"Gray","year":"2022","journal-title":"J Intensive Care Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"19409","DOI":"10.1038\/s41598-021-98734-x","article-title":"Effect of ondansetron on reducing ICU mortality in patients with acute kidney injury","volume":"11","author":"Guo","year":"2021","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jcrc.2021.07.015","article-title":"Effects of ondansetron use on outcomes of acute kidney injury in critically ill patients: an analysis based on the MIMIC-IV database","volume":"66","author":"Tao","year":"2021","journal-title":"J Crit care"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15204","article-title":"Mediators of neutrophil-lymphocyte ratio in the relationship between ondansetron pre-treatment and the mortality of ICU patients on mechanical ventilation: causal mediation analysis from the MIMIC-IV database","author":"Zhou","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nrneph.2017.119","article-title":"Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment","volume":"13","author":"Wang","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12967-022-03401-y","article-title":"Association between early ondansetron administration and in-hospital mortality in critically ill patients: analysis of the MIMIC-IV database","volume":"20","author":"Fang","year":"2022","journal-title":"J Transl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/pds.4960","article-title":"Identifying drug combinations associated with acute kidney injury using association rules method","volume":"29","author":"Nishtala","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.885137\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T06:21:34Z","timestamp":1655360494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.885137\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":23,"alternative-id":["10.3389\/fsurg.2022.885137"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2022.885137","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"article-number":"885137"}}